Labrador, Rejievhan .
HRN: 22-59-95 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/22/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
02/22/2023
03/01/2023
IV
217
Q24h
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes